Announcements Trials
Browse Landscape

Phase

Phase 2 30Phase 3 8Phase 1/2 6Phase 1 5Phase 2/3 3Phase 4 1

Status

Terminated 3Unknown 1Completed 1

Sponsor Class

OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3

Interventions

Carboplatin 9Paclitaxel 8Gemcitabine 8Cisplatin 8Cyclophosphamide 7Fluorouracil 6Docetaxel 5Capecitabine 5Granulocyte Colony-Stimulating Factor 4Etoposide 4Vinorelbine 3Stem Cell Transplantation 3Radiotherapy 3Pemetrexed 3Melphalan 3Leucovorin 3Filgrastim 3Erlotinib Hydrochloride 3Bone Marrow Transplantation 3Bevacizumab 3umbralisib 2ublituximab 2pembrolizumab 2peginterferon alfa-2b 2fludarabine 2Whole-Body Irradiation 2Trastuzumab 2Transplantation, Homologous 2Surveys and Questionnaires 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Terminated × Vinorelbine × Clear all
NCT00169104 2018-07-20

Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function

Dartmouth-Hitchcock Medical Center

Phase 2/3 Terminated
23 enrolled 10 charts
Breast

Breast Neoplasms

NCT02213744 2017-01-06

HERMIONE

Merrimack Pharmaceuticals

Phase 2/3 Terminated
113 enrolled
Breast

Breast Neoplasms

NCT00049660 2012-07-18

Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Terminated
47 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡